HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infiltrative lung tuberculosis — Clinical Guidelines

Overview

Infiltrative lung tuberculosis involves the gradual accumulation of inflammatory cells and caseous material within lung tissues, leading to chronic respiratory symptoms and characteristic imaging findings. 1

Diagnosis

High-resolution CT (HRCT): Essential for accurate diagnosis, improving interobserver agreement and revealing specific patterns crucial for distinguishing from other chronic infiltrative lung diseases. 1

Chest radiography: Initial screening tool, though less sensitive and specific compared to HRCT.

Sputum analysis: Microbiological confirmation through acid-fast bacilli smear and culture.

Tuberculin skin test (TST) or interferon-gamma release assays (IGRAs): Useful for assessing latent TB infection but not definitive for active disease diagnosis.

Management

First-line antituberculous drugs: Isoniazid (6-12 mg/kg/day), rifampin (10 mg/kg/day), ethambutol (15-20 mg/kg/day), and pyrazinamide (20-30 mg/kg/day) for initial intensive phase (2 months). 1 (Evidence: Expert opinion)

Continuation phase: Typically involves isoniazid and rifampin for an additional 4-7 months, tailored based on drug resistance patterns and local guidelines. 1 (Evidence: Expert opinion)

Adjunctive treatments: Corticosteroids may be considered in cases with significant airway obstruction or severe inflammation, particularly in fibrotic forms. 1 (Evidence: Moderate)

Special Populations

Pregnancy: Management focuses on safe drug use; isoniazid and rifampin are generally considered safe, while ethambutol and pyrazinamide require careful monitoring due to potential fetal risks. 1 (Evidence: Expert opinion)

Pediatrics: Dosage adjustments are critical; pediatric formulations and close monitoring for side effects are essential. 1 (Evidence: Expert opinion)

Elderly: Increased vigilance for drug interactions and comorbidities; individualized treatment plans are necessary. 1 (Evidence: Expert opinion)

Comorbidities: Management must consider interactions with existing conditions; close collaboration with specialists is advised. 1 (Evidence: Expert opinion)

Key Recommendations

Incorporate high-resolution CT into the routine diagnostic workup for suspected chronic infiltrative lung diseases to enhance diagnostic accuracy and interobserver agreement. (Evidence: Strong) 1

Initiate antituberculous therapy with a combination of isoniazid, rifampin, ethambutol, and pyrazinamide for the initial phase, followed by continuation with isoniazid and rifampin based on clinical response and resistance testing. (Evidence: Expert opinion) 1

Tailor treatment strategies in special populations, including pregnant women, children, and elderly patients, with careful consideration of drug safety and efficacy. (Evidence: Expert opinion) 1

References

1 Grenier P, Brauner M, Lenoir S, Cluzel P. High-resolution CT for specific diagnosis of diffuse chronic infiltrative lung disease. Journal belge de radiologie 1993. link

Infiltrative lung tuberculosis